Pharma has entered the chat.
(Side Effects May Include Brand Equity. Do Not Read If You Prefer the Disclaimer Era.)
The cultural calendar isn't optional anymore. Here's what to do about it before Labor Day.
Five years after COVID forced pharma to talk to the public directly, the corporate brand has stopped living inside advertising and started showing up as consumer experience. The 2026 Cannes Lions made it official. Here's what brand directors should be planning for 2027.
We're more than halfway through the year. South By came and went. Cannes Lions just wrapped. Comic-Con and Lollapalooza are around the corner. And every agency social post you read this summer is going to be full of polished activations from the same five categories. Beverage. Auto. Tech. Streaming. Fashion.
What most people haven't noticed yet is who else has been showing up alongside them.
Five years ago if you asked someone about a pharmaceutical company, they'd describe a sixty-second TV spot ending with a fair-balance voiceover about side effects you really did not need to hear over dinner. Today they can probably name three or four companies, and tell you something about the science behind them. What changed?
In 2019, public sentiment toward the pharmaceutical industry hit its lowest level in two decades of Gallup tracking. Only 27 percent of Americans had a positive view of the category, dead last among twenty-five major industries. The fair-balance voiceover was the brand. Then COVID forced pharma to do what it had spent decades avoiding: talk to the public directly about its science. Pfizer's Science Will Win was one of the first true company-forward campaigns the category had ever produced. It worked. Positive sentiment nearly doubled by the end of 2021 and has settled into a new normal well above the 2019 floor.
That was the catalyst. The five years since have been the build.
The People Foretold the Movement
In September 2022, Pfizer announced its first Global Chief Marketing Officer, Drew Panayiotou, recruited from Coca-Cola, Disney, and BBDO. The consumer-brand pedigree of the hire was without precedent in pharma. Under Panayiotou, Pfizer built its first global brand platform and ran Here's to Science during Super Bowl LVIII, the first Super Bowl ad by a pharma corporate brand. Panayiotou departed in mid-2024, succeeded by Susan Rienow who picked up the reigns.
Lilly followed soon after, elevating Lina Polimeni to its first Chief Corporate Brand Officer. Other pharmaceutical and wellness brands have followed.
When companies hire executives like these, they aren't tweaking the marketing mix. They're saying the corporate brand now has to show up where consumers actually live. The permission to be there has changed. So has the willingness to use it.
2026 Got Loud
The work is in market and the budgets are real. No industry-wide tally isolates pharma experiential, but the MM+M/Swoop Healthcare Marketers Trend Survey shows meetings and events spend rebounded in 2024 after a two-year pullback, and cross-industry EventTrack data puts event budgets at 10 to 30 percent of total marketing spend among companies actively scaling this channel.
Lilly is at the Olympics and SXSW.
Pfizer is layering broadcast and live activation. Every Inch Matters, their cancer-detection campaign, anchored on Al Pacino's voiceover at World Cancer Day, February 2026. On the live side, Pfizer has sponsored the Essence Festival of Culture since 2022, with booth activations on sickle cell disease, cardiac amyloidosis, and vaccine equity. Over 8,000 attendees visited the booth in 2024 alone, designed by Janine Lecour and animated by the Syncopated Ladies tap troupe under the theme "Tap In To Your Health."
“Essence helps us center the Black community as part of our work, meeting patients where they are to help overcome barriers and build trust, as part of Pfizer's mission to become the most trusted health brand.”Obi Ibekweh, Senior Director, Vaccines Adoption and Equity, Pfizer (Pfizer announcement, August 2024)
Novartis built the most complete corporate-brand-into-consumer-experience play of the year. As the NFL's first-ever corporate pharmaceutical partner, Novartis anchored a national prostate cancer initiative called Relax, It's a Blood Test across six layers. The Super Bowl LX commercial Relax Your Tight End featured George Kittle, Rob Gronkowski, and former Super Bowl-winning coach Bruce Arians, a prostate cancer survivor. Beneath the broadcast sat the consumer experience: a Super Bowl Experience popup in San Francisco with painting stations, relaxation pods, and calming music to lower fan anxiety around screening. Onsite PSA testing. Season-long community programs. My Cause My Cleats at season's end, with players spotlighting prostate cancer on custom cleats. Four months later, the work took the Pharma Grand Prix at Cannes Lions 2026, a week before this piece went live.
“We launched during the Super Bowl to meet audiences in a culturally relevant moment and help reduce anxiety around prostate cancer screening without diminishing the seriousness of the disease.”
Gail Horwood, Chief Marketing and Customer Experience Officer, Novartis U.S. (Fierce Pharma, June 2026)
Boehringer Ingelheim (BI) and Lilly co-staged It Takes 2, a chronic kidney disease awareness initiative at Art Basel Miami Beach in December 2025. An interactive street art pledge wall in the middle of the contemporary art world’s biggest commercial moment. One disease awareness, two partners, reaching the competitors the most culturally rarefied art venue on the calendar. Novo Nordisk extended its sponsorship of Team Novo Nordisk, a professional cycling team built entirely of riders living with type 1 diabetes, through 2031.
The Cannes Lions story is part of this. Medical-device makers and tech companies had dominated the Pharma Lions Grand Prix for most of the post-pandemic era. Big pharma had been losing its own category. Viatris broke the streak with the 2025 Grand Prix. Novartis took 2026. Viatris took Gold again. AstraZeneca was shortlisted. Back-to-back big pharma Grand Prix wins is the new pattern. In every case, the winning work went beyond a film: integrated across sponsorship, live experience, social, and PR.
The same shift is visible inside the medical congress world. OOH near major congresses increasingly runs corporate-brand creative rather than product-specific ads. Inside booths, Medical Affairs occupies more of the footprint than it used to. At ASCO 2026, AstraZeneca ran corporate brand interstitials that, for the first time we can recall, played simultaneously on the commercial and medical sides of the booth. Two audiences. One brand.
The detail on each of these activations, with what worked and why, is in the companion download.
Perception. Awareness. Sentiment.
That's what this is actually for. Sometimes the target is how the company is perceived. Sometimes it's how a disease state is understood. Often it's both at once.
None of this is new marketing theory. The agencies pharma is hiring now bring playbooks from Nike, Spotify, Netflix, and the Olympics. What's new is the permission to use them, and that pharma is using it through sponsorship and live experience, not only paid media.
There are two jobs experiential does, and the smartest brands run both. Corporate brand activations shift how the company is perceived. Lilly at the Olympics with Simone Biles. Pfizer with Pacino and Essence Fest. Novo Nordisk's cycling team. These build durable corporate equity that travels across the portfolio. Disease-state activations shift how a condition is understood. BI and Lilly at Art Basel Miami Beach. Novartis across the NFL season for prostate cancer. Two or more brands often pool spend, double reach, and avoid a brand-attribution war because the disease state is the hero. The validation often comes from outside pharma:
“We can help men detect prostate cancer earlier, expand equitable access to care, and fundamentally change what a diagnosis means for patients and their families.”
Shane Jacobson, CEO, American Cancer Society, on the Novartis NFL partnership (LBB / Novartis press release, January 2026)
That's a patient-advocacy CEO endorsing a pharma corporate initiative. The endorsement matters. The most effective programs do both jobs at once, and Novartis did exactly that. The corporate brand became a series of consumer experiences.
Most of what you are seeing in cultural venues is unbranded, by design. Pfizer's Every Inch Matters doesn't promote a specific oncology product. Novartis's Relax, It's a Blood Test doesn't promote Pluvicto. BI and Lilly's It Takes 2 doesn't promote Jardiance or Mounjaro. The MLR and OPDP burden is lighter on disease-state and corporate-brand work, letting companies enter conversations impossible inside a product label. Viatris's Make Love Last Grand Prix is the branded exception. The math is different for specialty and rare disease, but the principle holds: be in the rooms your audience is in.
For most therapeutic areas, the consumer is now in the room for every brand. Patients arrive at appointments having already met your category somewhere else. If they met it through your competitor, you're at a disadvantage in the conversation that follows. HCPs are not exempt either: the cardiologist watching Super Bowl LX, the oncologist walking through ASCO's host airport, the OB-GYN scrolling LinkedIn between appointments. They meet your brand in cultural contexts before your rep gets to the office. That HCP-specific dynamic deserves its own piece. The point for now is simpler: every audience pharma cares about is consumer-facing.
The fair pushback is that the cultural work isn't yet proving out in script lift or brand-tracking data, and that pharma is mimicking consumer-brand mechanics without the underlying business case. That's the honest skeptical read. The brands building anyway are betting that earned share-of-mind compounds over a multi-year horizon, that 2027 is when the curve bends, and that the companies waiting for proof will be following the leaders, not setting the pace. They could be wrong. They've decided being early is the lower-risk option.
Experiential is the channel that builds the kind of brand memory consumers can actually name. You can't reach that equity through broadcast and digital alone. You reach it by becoming an experience consumers walk into.
Plan It Like a Program, Not a Moment
The budget cycle isn't the constraint. Money gets scoped in Q2 and Q3. Big rocks go in by Labor Day. Plans lock in October. Agencies are briefed by January. That part of the rhythm is what it is.
The constraint is the planning. Even when budget is committed, the strategy, the creative, the asset architecture, the sponsorship deals, the on-site experience, and the measurement frame all have their own runway. Cultural inventory, the SXSW headline slots, the Art Basel presence, the Olympic tie-ins, the NFL community programs, the Super Bowl Experience footprints, sells a year in advance on a first-come basis. The brands that show up well at any of those venues in 2027 are the ones whose 2026 summer is spent planning, not spending.
The trap is treating any of this as a single moment. When a brand wants in, the internal conversation usually goes one of two ways. Either someone says "let's do something cultural at our next congress," which produces an expensive booth-lounge with a wellness theme and no actual cultural import. Or someone says "let's sponsor something at SXSW," which produces a check-writing exercise with no follow-through into the medical narrative and no measurable contribution to the business.
Neither builds what the leading companies are building: a connected program where cultural moments build brand equity, sponsorships create consumer experience, disease-awareness builds category, Medical Affairs deepens trust, and congress converts it all into HCP and patient action. Many layers, one strategy, one audience. Most pharma activation plans being drafted now have one. Maybe two. Almost none have all of them.
The 2026 Cannes Lions jury said it directly:
“What makes work Grand Prix? When the whole is more than the sum of great individual parts. And this work ticked all the boxes. Based on a relatable human truth. Appropriate to the audience. Deploying celebrity authentically. Integrated from the Super Bowl to Social to PR. Bold. Humorous. All while addressing a genuine issue.”
Tracey Brader, Chief Strategy and Innovation Officer at Omnicom Health and Pharma Lions Jury President, Cannes Lions 2026 (Official Cannes Lions announcement, June 2026)
That isn't a creative judgment. It's a structural one. The jury described a connected program. The spot was one layer of many. The corporate brand showed up as consumer experience at every touchpoint. That's what won.
The deeper trap is structural. The people who would need to build connected programs work in silos: Commercial, Medical Affairs, Market Access, Corporate Affairs, Brand, Comms, sponsorship, live experience. Each owns a piece of the audience and the budget. The companies building integrated programs have made internal connection a deliberate function, often at the CMO or CCBO level.
Launch teams feel this most acutely. A 2027 launch with no experiential infrastructure in 2026 isn't a launch. It's an announcement. The same logic applies to portfolio brands at every stage of maturity. A perception-shifting program in 2027 isn't built in October 2026. It's built this summer.
How We See It
Three principles separate a connected program from an expensive set of disconnected moments.
One audience strategy, multiple contexts.
Not separate strategies for separate rooms. One audience, your HCPs, your patients, your payers, your investors, humans needing different things from you in each context they meet you in.
Content architecture that lets assets travel.
A SXSW panel only matters if its outputs show up downstream in HCP-facing and patient-facing work. A Super Bowl Experience popup only matters if the brand follow-through extends past the weekend. That's a planning problem, not a creative one.
Measurement that crosses environments.
Badge scans aren't a frame. Neither are impressions. The brands closing the loop are building toward something more honest: earned reach against owned reach against HCP engagement against script lift, on a single timeline, across cultural and congress moments. Few have it fully wired yet. The ones moving in that direction will own the next wave of measurement.
Your Summer Homework
Two questions worth bringing into your next planning meeting
Whether or not you have a 2027 launch, this summer is the window for thinking about where experiential fits.
What perception, awareness, or sentiment do we need to shift in 2027, and where specifically are the live moments and sponsorship surfaces where we can earn it?
When we earn any of those moments, what's the asset architecture that carries it into the rest of our work?
if you want us to review your plans, we’re here to help
11 Zebras is offering a small number of complimentary 45-minute strategy sessions over the next six weeks for brand directors, medical affairs leaders, and agency principals thinking about how experiential fits 2027 plans. Bring your working brief, franchise priorities, or launch timeline. We'll come back within a week with a one-page read on where the gaps are, what's still bookable, and what would close the loop.
Pfizer showed the industry that pharma could operate as a consumer brand. The companies that have followed are showing what it looks like when the corporate brand commits to that posture as strategy, not tactic, and as live experience, not only as paid media. Novartis just collected a Cannes Grand Prix for proving the integrated version of that argument. The question every modern pharma brand should be asking right now is whether they're set up to compete on the same field, or showing up to it late.
Contact us: Chris Metzger & Julie Teplitzky | hello@11zebras.com